eXmoor, the expert cell and gene therapy (CGT) services company (Bristol, England), has announced an initial investment of £12m ($17m) from specialist healthcare investment firm MVM Partners (“MVM”), to enable eXmoor’s ambitious expansion plans. This will create a new dedicated 50,000 ft2 CGT process development and clinical manufacturing facility in Bristol (UK). Source: eXmoor press release 20/3/2021